ArticleChemical research in toxicology2014
Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin.
Article in Chemical research in toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 24 citations in OpenAlex.
- Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy.Investigational new drugs · 2022Review
- Chronic Kidney Disease and Exposure to Nephrotoxic Metals.International journal of molecular sciences · 2017Review
- Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Here, we report the identification of dimethylarsinothioyl glutathione (DMMTA(V)(GS)) as a metabolite in cellular extracts of dimethyarsinous glutathione (Darinaparsin, DMA(III)(GS)) treated human multiple myeloma (MM) cell lines. Co-elution of sulfur and arsenic on the inductively coupled plasma mass spectrometer (ICP-MS) indicated the presence of sulfur along with arsenic in the newly observed unidentified molecule on the speciation chromatograms of cell lines treated with DMA(III)(GS). Liquid chromatography-electrospray ionization-mass spectrometry of the unknown peak in the MS and tandem MS modes revealed molecular ion peaks at m/z = 443.9 and 466.0, corresponding to [DMMTA(V)(GS) + H](+) and [DMMTA(V)(GS) + Na](+), as well as peaks at 314.8 for the loss of glutamic acid and 231.1 for the loss of glycine. In addition, peaks were observed at 176.9 corresponding to cysteine and glycine adducts and at 137.1 for the [C2H6AsS](+) ion. An increase in the peak area of the unidentified peak was observed upon spiking the cell extracts with a standard of DMMTA(V)(GS). Heat deactivation of MM cells prevented the formation of DMMTA(V)(GS) raising the possibility of its formation via an enzymatic reaction. Formation studies in DMA(III)(GS) treated MM cells revealed the dependence of DMMTA(V)(GS) formation on the depletion of DMA(III)(GS). The presence of 5 mM glutathione prevented its formation, indicating that DMA(III), a dissociation product of DMA(III)(GS), is likely a precursor for the formation of DMMTA(V)(GS). DMMTA(V)(GS) was observed to form under acidic and neutral pH conditions (pH 3.0-7.4). In addition, DMMTA(V)(GS) was found to be stable in cell extracts at both acidic and neutral pH conditions. When assessing the toxicity by exposing multiple myeloma cells to arsenicals externally, DMMTA(V)(GS) was found to be much less toxic than DMA(III)(GS) and DMMTA(V), potentially due to its limited uptake in the cells (10 and 16% of the uptakes of DMA(III)(GS) and DMMTA(V), respectively).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.